Log in to search using one of your social media accounts:

 

Biosimilar Cancer Drug Threat Closing in for Roche Biosimilar Cancer Drug Threat Closing in for Roche
The long-heralded threat of cut-price competition to its top-selling biological cancer medicines is finally becoming a reality for Roche, the world's biggest maker of oncology treatments.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 19, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Imatinib a Double-Edged Sword for Pregnant CML Patients Imatinib a Double-Edged Sword for Pregnant CML Patients
On the one hand, imatinib keeps the CML in check; on the other hand, it carries a risk for fetal congenital malformation if taken during pregnancy.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 19, 2017 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Futile: Prostate Cancer Vaccine Phase 3 Trial Ends Futile: Prostate Cancer Vaccine Phase 3 Trial Ends
Prostvac is an immunotherapy designed to induce T-cell responses and thus kill prostate cancer cells. As a monotherapy, it is not effective.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 19, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

5T4-targeted Immunotherapy Promising in Metastatic Colorectal Cancer 5T4-targeted Immunotherapy Promising in Metastatic Colorectal Cancer
Immunotherapy with modified vaccinia Ankara-5T4 (MVA-5T4, TroVax) may improve survival in patients with metastatic colorectal cancer, researchers report.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 18, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

New Path for Lung Cancer Treatment?
(MedPage Today) -- Targeting inflammation linked to fewer lung cancer deaths (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - September 18, 2017 Category: Hematology Source Type: news

Severe Health Problems Plague Survivors of Childhood CA Severe Health Problems Plague Survivors of Childhood CA
Specialized healthcare delivery is needed for diverse subgroups of adult cancer survivors with complex medical needs, say researchers.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 18, 2017 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

' Big Alcohol' Deliberately Downplays Cancer Risk'Big Alcohol' Deliberately Downplays Cancer Risk
Global alcohol producers are downplaying the cancer risks associated with drinking in order to protect profits, just like tobacco firms did, say public health experts.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 18, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Medical News Today: How to stop bleeding: Eight effective home remedies
In this article, learn about eight effective home remedies to stop bleeding, including tea, ice, and mouthwash. How can infection be prevented? (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - September 17, 2017 Category: Consumer Health News Tags: Blood / Hematology Source Type: news

10 Questions to Challenge Your Medical News Savvy
(MedPage Today) -- Weekly News Quiz: September 8-14 (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - September 17, 2017 Category: Hematology Source Type: news

More Than Okay to Reduce Sorafenib Dose for Liver Cancer More Than Okay to Reduce Sorafenib Dose for Liver Cancer
Initially reducing the dosage of the oral therapy did not compromise overall survival in hepatocellular carcinoma and had important benefits.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 15, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

EU Panel Likes an Array of Cancer Products EU Panel Likes an Array of Cancer Products
The Committee for Medicinal Products for Human Use recommended granting marketing authorization to branded, generic, and biosimiliar products.International Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 15, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

Medical News Today: Hyperemia: Causes, symptoms, and treatment
What is hyperemia? In this article, learn about the different types of hyperemia, including passive and active hyperemia. How can it be prevented? (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - September 15, 2017 Category: Consumer Health News Tags: Blood / Hematology Source Type: news

Phosphate Disease Yields to Burosumab (CME/CE)
(MedPage Today) -- Both adults and children with X-linked hypophosphatemia benefited from monoclonal antibody treatment (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - September 14, 2017 Category: Hematology Source Type: news

New Drug Approved for Relapsed Lymphoma: Copanlisib New Drug Approved for Relapsed Lymphoma: Copanlisib
Patients with follicular lymphoma who have relapsed after at least two prior therapies now have a new option.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 14, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

First Oncology Biosimilar Approved in US: Bevacizumab First Oncology Biosimilar Approved in US: Bevacizumab
The FDA has approved the first biosimilar for use in the treatment of cancer: Myasi, or bevacizumab-awwb (equivalent to Avastin).News Alerts (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 14, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

$45 Million for Patients Harmed by Disgraced Breast Surgeon $45 Million for Patients Harmed by Disgraced Breast Surgeon
The private healthcare company that employed disgraced breast cancer surgeon Ian Paterson, who is now in jail, will pay compensation to his patients.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 14, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Marital Status, Gender Tied to RCC T and Outcomes: Clin Onc News Report
(MedPage Today) -- Also, new AUA guidelines for handling localized renal masses (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - September 14, 2017 Category: Hematology Source Type: news

Marital Status, Gender Tied to RCC Tx and Outcomes: Clin Onc News Report
(MedPage Today) -- Also, new AUA guidelines for handling localized renal masses (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - September 13, 2017 Category: Hematology Source Type: news

Global Mesothelioma Deaths Remain High Despite Poor Data
An estimated 38,400 people around the world will die this year from mesothelioma cancer, according to a report recently published in Occupational & Environmental Medicine. The estimation by the international peer-reviewed journal included 230 countries. Data used for the study came from the World Health Organization’s (WHO) Mortality Database and extrapolated information based on gender- and age-specific death rates. “The global burden of mesothelioma is real,” Dr. Ken Takahashi, director of Asbestos Diseases Research Institute, University of Sydney Gate 3, Australia, told Asbestos.com. “It is v...
Source: Asbestos and Mesothelioma News - September 13, 2017 Category: Environmental Health Authors: Matt Mauney Tags: Asbestos Diseases Research Institute asbestos-related lung cancer Australia mesothelioma Bangladesh Dr. Christina Fitzmaurice Dr. Ken Takahashi Global Burden of Disease Mesothelioma death rate mesothelioma latency period mesothelioma uni Source Type: news

Nivolumab-Ipilimumab Combo for Melanoma: 3-Year Survival Data Nivolumab-Ipilimumab Combo for Melanoma: 3-Year Survival Data
Three-year survival rates with advanced melanoma are 52% with nivolumab and 34% with ipilimumab, but 58% with a sequential combination of the two, according to the latest results comparing the two anticancer biologics separately and together.Reuters Health Information (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 13, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

USPSTF Has New Draft Guidance for Cervical Cancer Screening USPSTF Has New Draft Guidance for Cervical Cancer Screening
The only major change is that the USPSTF no longer recommends testing in women 30 years and older.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 12, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

FDA Extends Holds in Immunotherapy Trials in Blood Cancers FDA Extends Holds in Immunotherapy Trials in Blood Cancers
The Food and Drug Administration has slowed or fully halted more trials of immunotherapies in multiple myeloma and other blood cancersMedscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 12, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

ASCO Issues Guidelines on Patient-Clinician Communication ASCO Issues Guidelines on Patient-Clinician Communication
New guidelines from the American Society of Clinical Oncology (ASCO) offer strategies and recommendations for improving patient-clinician communication.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 12, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

36% Price Drop With a Generic Oral Chemo: Good Enough? 36% Price Drop With a Generic Oral Chemo: Good Enough?
Capecitabine was one of the first oral chemotherapies to come off patent, and the generic version has been quickly accepted.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 12, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

New Adjuvant Option for BRAF Melanoma New Adjuvant Option for BRAF Melanoma
Combined targeting with BRAF and MEK inhibitors will soon move into the adjuvant setting for treating BRAF-V300-positive stage III melanoma, say experts.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 12, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Clear Benefit With Adjuvant Nivolumab in Resected Melanoma Clear Benefit With Adjuvant Nivolumab in Resected Melanoma
Adjuvant nivolumab significant improves relapse-free survival and reduces toxicity in comparison with ipilimumab in stage III/IV resected melanoma for patients at risk for relapse, trial results reveal.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 12, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Medical News Today: Advantages and disadvantages of donating blood
In this article, learn about the advantages and disadvantages of donating blood, including how it affects the body, how the process works, and preparation. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - September 12, 2017 Category: Consumer Health News Tags: Blood / Hematology Source Type: news

Queens Medical Associates Shares Insight on Pain for Pain Awareness...
Queens oncology and hematology center provides tips on finding pain relief(PRWeb September 12, 2017)Read the full story at http://www.prweb.com/releases/2017/09/prweb14687540.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - September 12, 2017 Category: Pharmaceuticals Source Type: news

Expert Perspectives: ESMO 2017 Changes Lung Cancer Practice Expert Perspectives: ESMO 2017 Changes Lung Cancer Practice
Several lung cancer experts from the US and Europe provide their perspective on a variety of important lung trials presented at ESMO 2017.Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 11, 2017 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news

Neurologic AEs on Rise as Checkpoint Inhibitors Evolve Neurologic AEs on Rise as Checkpoint Inhibitors Evolve
Potentially lethal immune-related adverse events (AEs) are expected to increase as anti-PD-1 therapies for solid tumors expand to include other cancers.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 11, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

R & D Investment Does Not Justify High Cost of Cancer Drugs R & D Investment Does Not Justify High Cost of Cancer Drugs
A new analysis found that the revenue from cancer drugs greatly exceeds the investment to develop them.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 11, 2017 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

R and D Investment Does Not Justify High Cost of Cancer Drugs R and D Investment Does Not Justify High Cost of Cancer Drugs
A new analysis found that the revenue from cancer drugs greatly exceeds the investment to develop them.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 11, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Hint of Survival Gain With Ramucirumab in Urothelial Cancer Hint of Survival Gain With Ramucirumab in Urothelial Cancer
Patients with progressive urothelial cancer after platinum-based chemotherapy may benefit with the antiangiogenesis drug ramucirumab, although the absolute gain is small, trial results suggest.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 11, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Cancer Patients Struggle to Understand Clinical Trials Cancer Patients Struggle to Understand Clinical Trials
A nationwide study of cancer patients in Ireland found that many did not understand concepts of randomization or clinical equipoise, even when they had participated.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 11, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Abemaciclib: First-Line CDK4/6 Inhibitor for Breast Cancer Abemaciclib: First-Line CDK4/6 Inhibitor for Breast Cancer
Abemaciclib, the third CDK4/6 inhibitor, in combination with endocrine therapy shows significant benefit for the first-line treatment of HR+ HER2- advanced breast cancer.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 11, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Chemoradiotherapy Remains Standard of Care in Cervical Cancer Chemoradiotherapy Remains Standard of Care in Cervical Cancer
Chemoradiotherapy remains the standard of care for cervical cancer patients with locally advanced disease, concludes an Indian trial that compared it to neoadjuvant chemotherapy.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 11, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Morning Break: Irma and Labor; Eclipse Eye Damage; Ditching Prescriptions
(MedPage Today) -- Health news and commentary from around the Web gathered by the MedPage Today staff (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - September 11, 2017 Category: Hematology Source Type: news

Immunotherapy Changes First-Line Paradigm in Advanced RCC Immunotherapy Changes First-Line Paradigm in Advanced RCC
For the first time, sunitinib has been beaten in a phase 3 trial; the combination of nivolumab and ipilimumab showed a significant improvement in overall survival.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 11, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Genomic Testing for Localized Prostate Cancer Genomic Testing for Localized Prostate Cancer
What role might currently available genetic testing options have in the risk stratification of localized prostate cancer?Current Opinion in Urology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 11, 2017 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

EGFR-Mutant NSCLC Gains New First-Line Treatment
(MedPage Today) -- PFS doubled with osimertinib versus standard therapy (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - September 10, 2017 Category: Hematology Source Type: news

' Spare Tire' Ups Cancer Risk More Than High BMI, Fat Percent'Spare Tire' Ups Cancer Risk More Than High BMI, Fat Percent
A Danish observatory study followed postmenopausal woman for 12 years and found that central obesity, but not BMI and fat percentage, places women at an increased risk for cancer diagnosis.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 10, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Taselisib Added to Letrozole Boosts Response in Breast Cancer Taselisib Added to Letrozole Boosts Response in Breast Cancer
Taselisib, a PIK3CA targeted agent, in combination with letrozole significantly increased overall response rates in postmenopausal women with ER+/HER2- stage I-III operable breast cancer. ORRs were more robust in patients with PIK3CA mutations.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 10, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

PI3K Inhibitor Ups Response in Early Breast Cancer
(MedPage Today) -- Response odds doubled in PIK3CA-mutant, ER-positive tumors (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - September 10, 2017 Category: Hematology Source Type: news

Durvalumab Boots PFS Even in Stage 3 Lung Cancer Durvalumab Boots PFS Even in Stage 3 Lung Cancer
Immunotherapy is continuing its march: the first trial of an anti-PD-L1 inhibitor in stage 3 non-small cell lung cancer has shown an impressive increase in progression-free survival.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 9, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Osimertinib Poised To Be New First-line Standard EGFRm NSCLC Osimertinib Poised To Be New First-line Standard EGFRm NSCLC
Osimertinib, a third-generation EGFR inhibitor, significantly improved PFS over current standard-of-care therapies in advanced NSCLC harboring EGFR mutations.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 9, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Novel Tool Identifies Palliative Care Needs Early in Cancer Novel Tool Identifies Palliative Care Needs Early in Cancer
Patients with cancer can have palliative care needs early after diagnosis, even in those with a good functional status, the results of a pilot study to integrate such care into oncological services show.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 9, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Extent of Remnant Liver Ischemia May Predict Survival After Colorectal Liver Metastases Extent of Remnant Liver Ischemia May Predict Survival After Colorectal Liver Metastases
Reuters Health Information (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - September 8, 2017 Category: Radiology Tags: Hematology-Oncology News Source Type: news

chemoWave: Patients Data-Sharing With Clinicians chemoWave: Patients Data-Sharing With Clinicians
A lot can go wrong when cancer patients undergo weeks of chemotherapy. A new app allows for symptom reporting and other vital communication.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 8, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Alectinib Activity in CNS Metastases in Patients With ALK+ NSCLC Alectinib Activity in CNS Metastases in Patients With ALK+ NSCLC
Two studies report impressive activity for the ALK inhibitor, alectinib, in patients with advanced ALK+ NSCLC -- both in treatment-naive patients and those who have progressed on prior therapy.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 8, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

MIRO: Minimally Invasive Surgery for Esophageal Cancer MIRO: Minimally Invasive Surgery for Esophageal Cancer
Patients with resectable esophageal cancer should undergo hybrid minimally invasive surgery, urge experts after a trial showed it markedly reduce postoperative morbidity vs open surgery.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 8, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news